Can TILs supplement the TNM staging system (as TNM-Immune)?

Alhadi Almangush^{1

2

3

4}, Antti A Mäkitie^{5

6

7}, Ilmo Leivo^{8

9}

Affiliations

¹ Department of Pathology, University of Helsinki, P.O. Box 21, FI-00014, Helsinki, Finland. alhadi.almangush@helsinki.fi.
² Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. alhadi.almangush@helsinki.fi.
³ Institute of Biomedicine, Pathology, University of Turku, Kiinamyllynkatu 10 D 5035, 20520, Turku, Finland. alhadi.almangush@helsinki.fi.
⁴ Faculty of Dentistry, Misurata University, Misurata, Libya. alhadi.almangush@helsinki.fi.
⁵ Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
⁶ Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 263, FI-00029 HUS, Helsinki, Finland.
⁷ Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
⁸ Institute of Biomedicine, Pathology, University of Turku, Kiinamyllynkatu 10 D 5035, 20520, Turku, Finland.
⁹ Turku University Central Hospital, 20521, Turku, Finland.

Comment

Alhadi Almangush et al. Br J Cancer. 2023 Sep.

. 2023 Sep;129(5):739-740.

doi: 10.1038/s41416-023-02368-x. Epub 2023 Jul 28.

Alhadi Almangush^{1

2

3

4}, Antti A Mäkitie^{5

6

7}, Ilmo Leivo^{8

9}

¹ Department of Pathology, University of Helsinki, P.O. Box 21, FI-00014, Helsinki, Finland. alhadi.almangush@helsinki.fi.
² Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. alhadi.almangush@helsinki.fi.
³ Institute of Biomedicine, Pathology, University of Turku, Kiinamyllynkatu 10 D 5035, 20520, Turku, Finland. alhadi.almangush@helsinki.fi.
⁴ Faculty of Dentistry, Misurata University, Misurata, Libya. alhadi.almangush@helsinki.fi.
⁵ Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
⁶ Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 263, FI-00029 HUS, Helsinki, Finland.
⁷ Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
⁸ Institute of Biomedicine, Pathology, University of Turku, Kiinamyllynkatu 10 D 5035, 20520, Turku, Finland.
⁹ Turku University Central Hospital, 20521, Turku, Finland.

No abstract available

Conflict of interest statement

The authors declare no competing interests.

Tumour-infiltrating lymphocytes: from prognosis to treatment selection.
Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Brummel K, et al. Br J Cancer. 2023 Feb;128(3):451-458. doi: 10.1038/s41416-022-02119-4. Epub 2022 Dec 23. Br J Cancer. 2023. PMID: 36564565 Free PMC article.

1. Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;128:451–8. doi: 10.1038/s41416-022-02119-4. - DOI - PMC - PubMed
1. Taube JM. Emerging immunologic biomarkers: setting the (TNM-immune) stage. Clin Cancer Res. 2014;20:2023–5. doi: 10.1158/1078-0432.CCR-14-0328. - DOI - PMC - PubMed
1. Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52:55–81. doi: 10.1016/j.immuni.2019.12.018. - DOI - PubMed
1. Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, et al. Stromal CD8+ T-cell density – a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res. 2015;21:2635–43. doi: 10.1158/1078-0432.CCR-14-1905. - DOI - PubMed
1. Almangush A, Bello IO, Heikkinen I, Hagstrom J, Haglund C, Kowalski LP, et al. Improving risk stratification of early oral tongue cancer with TNM-immune (TNM-I) staging system. Cancers (Basel) 2021;13:3235. doi: 10.3390/cancers13133235. - DOI - PMC - PubMed